Cabaletta Bio, Inc. (CABA) Dividend History

Company News

• Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

  Cabaletta Bio announces positive clinical data for its rese-cel therapy in patients with myositis, lupus, and scleroderma, with most patients achieving clinically meaningful responses while off immunomodulators and steroids. The company plans to initiate registrational trials and engage with the FDA on regulatory pathways.

  GlobeNewswire Inc.
• US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode

  US stock futures are pointing to a higher open on Friday as investors look to end November on a positive note. Analysts suggest that December has historically been a strong month for markets, with only one instance of it being the worst month in the last 95 years.

  Benzinga

  Featured Companies: BTDR FRO QQQ RGTI SPY
• Wall Street Breakfast: The Week Ahead

  Discover the upcoming events and earnings reports in the financial market, including notable companies like Disney, Tyson Foods, and Uber.

  Seeking Alpha

  Featured Companies: AAPL ABNB AFRM AMC AMCX AZTR BYND CPNG CRGX CRSP DBX DDOG DIS DJT EA EDIT ENB ET FATE G GFS H HG IBM KNSL KOPN LAZR MCK O PLTR RACE RBLX REGN RIVN SHOP TSLA TSN TTD UBER USFD VRTX WBD ZYXI
• Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy

  Shares of small biotech companies involved in CAR-T therapies plunged Tuesday as the FDA said it was investigating potential cancer risks.

  MarketWatch

  Featured Companies: BMY GILD
• Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?

  Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

  Zacks Investment Research

  Featured Companies: KALV